A 58365 A

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571139

CAS#: 87896-52-4 (A)

Description: A 58365 A is an angiotensin converting enzyme (ACE) inhibitor isolated from Streptomyces chromofuscus. It is used to treat hypertension and congestive heart failure.


Price and Availability

Size
Price

Size
Price

Size
Price

A 58365A is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 571139
Name: A 58365 A
CAS#: 87896-52-4 (A)
Chemical Formula: C12H13NO6
Exact Mass: 267.0743
Molecular Weight: 267.24
Elemental Analysis: C, 53.93; H, 4.90; N, 5.24; O, 35.92


Related CAS #: 87896-52-4 (A)   87896-53-5 (B)  

Synonym: A 58365A; A-58365A; A58365A

IUPAC/Chemical Name: 6-Indolizinepropanoic acid, 3-carboxy-1,2,3,5-tetrahydro-8-hydroxy-5-oxo-, (-)-

InChi Key: HMWIHWAAIYAMFZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C12H13NO6/c14-9-5-6(1-4-10(15)16)11(17)13-7(9)2-3-8(13)12(18)19/h5,8,14H,1-4H2,(H,15,16)(H,18,19)

SMILES Code: O=C(O)CCC1=CC(O)=C2CCC(C(O)=O)N2C1=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Vinazzer H, Farine JC. Double-blind cross-over study of the effect of sultosilic acid piperazine salt (A-585) and bezafibrate in primary hyperlipoproteinemia. Atherosclerosis. 1983 Nov;49(2):109-18. PubMed PMID: 6686778.

2: Vinazzer H. [Comparison of the antilipemic effect of bezafibrate with that of piperazine-sultosilate (A 585). A crossed double-blind study]. Wien Klin Wochenschr. 1984 Dec 21;96(24):889-93. German. PubMed PMID: 6152088.

3: Rodríguez L, Demestre I, Sagarra R, Laporte J, Esteve A. [Toxicologic study of piperazine sultosylate (A-585)]. Arch Farmacol Toxicol. 1979 Dec;5(3):281-3.Spanish. PubMed PMID: 546355.

4: Casellas Bernat A, Ribas Grau M, Casellas Bernat G, Riera de Barcia L, Alou Llado M, Solivellas Antich S. [Clinical effectiveness of piperazine sultosylate in the hyperlipidemias]. Rev Clin Esp. 1981 Apr 25;161(1):5-8. Spanish. PubMed PMID: 7255818.

5: Rodríguez L, Roser R, Palacios G, Sagarra R, Esteve A. [Hypolipemic activity of piperazine sultosylate (A-585) in the rat and chicken]. Arch Farmacol Toxicol. 1979 Dec;5(3):272-4. Spanish. PubMed PMID: 546353.

6: Rodríguez L, Parés S, Laporte J, Roser R, Esteve J. [Effect of piperazine sultosylate (A-585) on hypertriglyceridemia induced by ethanol in man]. Arch Farmacol Toxicol. 1979 Dec;5(3):235-7. Spanish. PubMed PMID: 546346.

7: Masana L, Villoria J, Sust M, Ros E, Plana N, Pérez-Jiménez F, Franco M, Oliván JJ, Pintó X, Videla S. Treatment of type IIb familial combined hyperlipidemia with the combination pravastatin-piperazine sultosilate. Eur J Pharmacol. 2004 Aug 2;496(1-3):205-12. PubMed PMID: 15288592.